Compare SHG & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHG | RMD |
|---|---|---|
| Founded | 1982 | 1989 |
| Country | South Korea | United States |
| Employees | N/A | 10600 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9B | 28.4B |
| IPO Year | 2003 | N/A |
| Metric | SHG | RMD |
|---|---|---|
| Price | $71.84 | $191.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $292.56 |
| AVG Volume (30 Days) | 235.9K | ★ 1.4M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.12% | 1.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.16 | $10.60 |
| Revenue Next Year | $3.88 | $7.41 |
| P/E Ratio | ★ $9.79 | $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.28 | $180.27 |
| 52 Week High | $73.80 | $293.81 |
| Indicator | SHG | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 41.72 |
| Support Level | $65.55 | $190.25 |
| Resistance Level | $72.88 | $197.41 |
| Average True Range (ATR) | 1.28 | 5.86 |
| MACD | -0.02 | -1.32 |
| Stochastic Oscillator | 45.76 | 2.98 |
Shinhan Financial Group Co Ltd is a Korean banking group. Along with its subsidiaries the company provides, comprehensive financial services which consist of commercial banking services, credit card services, securities services, insurance, credit services, and asset management services, including securities investment trust management, investment advisory, call transaction, domestic and foreign private equity fund business, and other services. The majority of the revenue is generated from its Banking business which includes retail, corporate, international, and other banking services the company offers.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.